Skip to main content
SpringerLink
Log in

Serelaxin zur Therapie der akuten Herzinsuffizienz (RELAX-AHF)

Eine vielversprechende Option?

H1 Serelaxin zur Therapie der akuten Herzinsuffizienz (RELAX-AHF)

H2 Eine vielversprechende Option?

  • Notfall aktuell - Für Sie gelesen
  • Published:
Notfall + Rettungsmedizin Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Authors/Task Force Members, McMurray JJV, Adamopoulos S et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847

    Article  Google Scholar 

  2. Cotter G, Metra M, Milo-Cotter O et al (2008) Fluid overload in acute heart failure – re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 10:165–169

    Article  PubMed  Google Scholar 

  3. Du XJ, Bathgate RA, Samuel CS et al (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 7:48–58

    Article  PubMed  CAS  Google Scholar 

  4. Konstam MA, Thethi T, Fonseca V et al (2012) RELAX-AHF: rising from the doldrums in acute heart failure Lancet 381:5–6

    Google Scholar 

  5. Ramirez A, Abelmann WH (1974) Cardiac decompensation. N Engl J Med 290:499–501

    Article  PubMed  CAS  Google Scholar 

  6. Roger VL, Go AS, Lloyd-Jones DM et al (2012) Executive summary: heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 125:188–197

    Article  PubMed  Google Scholar 

  7. Teerlink JR, Cotter G, Davison BA et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39

    Article  PubMed  CAS  Google Scholar 

  8. Metra M, Cotter G, Davison BA et al (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61:196–206

    Article  PubMed  CAS  Google Scholar 

  9. Breidthardt T, Noveanu M, Potocki M et al (2010) Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study. J Intern Med 267(3):322–330

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

 

Conflict of interest

M. Christ works as a lecturer for Novartis AG. J. Schmidt declares that she has no conflict of interest.

 

This article does not contain any studies with human or animal subjects.

Author information

Authors and Affiliations

  1. Klinik für Notfall- und Internistische Intensivmedizin, Klinikum Nürnberg, Prof-Ernst-Nathan-Straße 1, 90419, Nürnberg, Deutschland

    M. Christ & J. Schmidt

Authors
  1. M. Christ
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Christ.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christ, M., Schmidt, J. Serelaxin zur Therapie der akuten Herzinsuffizienz (RELAX-AHF). Notfall Rettungsmed 16, 305–308 (2013). https://doi.org/10.1007/s10049-012-1682-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10049-012-1682-6

Search

Navigation